Ipsen Biopharmaceuticals, Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$86.1M
Doctors Paid
21,651
Transactions
75,758
2024 Total
$16.7M
Payment Breakdown by Category
Research$68.1M (79.0%)
Consulting$2.5M (2.9%)
Food & Beverage$1.9M (2.2%)
Travel$1.5M (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $68.1M | 3,287 | 79.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9.4M | 2,936 | 10.9% |
| Consulting Fee | $2.5M | 1,171 | 2.9% |
| Food and Beverage | $1.9M | 63,238 | 2.2% |
| Travel and Lodging | $1.5M | 3,562 | 1.7% |
| Education | $1.3M | 960 | 1.5% |
| Space rental or facility fees (teaching hospital only) | $917,101 | 419 | 1.1% |
| Honoraria | $648,388 | 185 | 0.8% |
Payments by Type
Research
$68.1M
3,287 transactions
General
$18.1M
72,471 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naive Metastatic Pancreatic Cancer (GIANT) | $5.0M | 0 | 8 |
| A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma | $3.0M | 0 | 14 |
| NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer | $2.9M | 0 | 42 |
| A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | $2.0M | 0 | 3 |
| Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin | $2.0M | 0 | 13 |
| Total Neoadjuvant NALIRIFOX Plus Ablative Dose Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | $1.7M | 0 | 7 |
| Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma | $1.6M | 0 | 14 |
| A Phase II Study of Neoadjuvant NAPOX Followed by Chemoradiation with Paclitaxel and Carboplatin in Locally Advanced Esophagogastric Cancer | $1.6M | 0 | 18 |
| A Phase II Study of Neoadjuvant NAPOX Followed by Chemoradiation With Paclitaxel and Carboplatin in Locally Advanced Esophagogastric Cancer | $1.4M | 0 | 14 |
| A Single Arm Phase Ib/II Multi-Center Study of Nivolumab in Combination With Nanoliposomal-Irinotecan, 5-Fluorouracil, and Leucovorin as Second Line Therapy for Patients With Advanced Biliary Tract Cancer | $1.3M | 0 | 17 |
| A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | $1.3M | 0 | 30 |
| A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naive Metastatic Pancreatic Cancer (GIANT | $1.2M | 0 | 1 |
| A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers | $1.2M | 0 | 12 |
| A Phase II Study to Evaluate the Efficacy of Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067 | $1.2M | 0 | 8 |
| PHASE II STUDY OF NANOLIPOSOMAL IRINOTECAN WITH TAS102 AND BEVACIZUMAB FOR PATIENTS WITH METASTATIC COLORECTAL CANCER | $1.2M | 0 | 6 |
| Exploratory Phase II Study of Lanreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA) | $1.1M | 0 | 7 |
| A RANDOMIZED PHASE I/II STUDY OF ONIVYDE IN COMBINATION WITH TALAZOPARIB OR TEMOZOLOMIDE IN CHILDREN WITH RECURRENT SOLID MALIGNANCIES AND EWING SARCOMA | $1.0M | 0 | 4 |
| A Phase II trial of tazemetostat plus mosunetuzumab in untreated follicular lymphoma | $999,050 | 0 | 6 |
| Alternating Neoadjuvant Gemcitabine-Nab-Paclitaxel and Nanoliposomal Irinotecan (Nal-IRI) With 5-Fluorouracil and Folinic Acid (Leucovorin) Regimens in Resectable and Borderline Resectable Pancreatic Cancer | $926,072 | 0 | 5 |
| A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | $885,477 | 0 | 11 |
| A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide AutogelDepot 120 mg Plus BSC vs. Placebo Plus BSC for Tumor Control in Subjects With Well Differentiated, Metastatic andor Unresectable, Typical or Atypical, Lung Neuroendocrine Tumors | $850,017 | 0 | 363 |
| Phase IbII Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors | $809,479 | 0 | 6 |
| A Phase III Study of TrifluridineTipiracil TAS102 in Combination With Nanoliposomal Irinotecan NAL-IRI in Advanced GI Cancers | $794,965 | 0 | 11 |
| NAPOLI-2Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer | $794,016 | 0 | 9 |
| Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | $777,741 | 0 | 16 |
| A Single Arm Phase IbII Multi-Center Study of Nivolumab in Combination With Nanoliposomal-Irinotecan, 5-Fluorouracil, and Leucovorin as Second Line Therapy for Patients With Advanced Biliary Tract Cancer | $774,284 | 0 | 7 |
| A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) | $718,269 | 0 | 9 |
| A Single Arm Phase IbII Multi-Center Study ofNivolumab in Combination With Nanoliposomal-Irinotecan, 5-Fluorouracil, and Leucovorinas Second Line Therapy for Patients With Advanced Biliary Tract Cancer | $686,140 | 0 | 3 |
| A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinumtoxinA in Paediatric Lower Limb Spasticity. | $673,007 | 1 | 169 |
| Alternating neoadjuvant Gemcitabine-Nab-Paclitaxel and Nanoliposomal irinotecan with 5-Fluorouracil and folinic acid regimens in resectable and borderline resectable pancreatic cancer | $658,964 | 0 | 6 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Melissa Palmer, M.d, M.D | Gastroenterology | Plainview, NY | $394,335 | $0 |
| Michael Morse, M.d, M.D | Hematology & Oncology | Durham, NC | $394,233 | $0 |
| Alexandria Phan, M.d, M.D | Medical Oncology | Milwaukee, WI | $357,079 | $0 |
| Dr. George Kim, M.d, M.D | Medical Oncology | Gainesville, FL | $326,766 | $0 |
| Michael Saulino, Md, MD | Physical Medicine & Rehabilitation | Elkins Park, PA | $283,273 | $0 |
| Monica Verduzco-Gutierrez, M.d, M.D | Physical Medicine & Rehabilitation | San Antonio, TX | $275,965 | $0 |
| Omar Barakat, Md, MD | Surgery | Houston, TX | $273,910 | $0 |
| Dr. Maen Abdelrahim, Md, MD | Internal Medicine | Houston, TX | $249,247 | $0 |
| Ravi Paluri, Md, MD | Hematology & Oncology | Winston Salem, NC | $212,332 | $0 |
| Dr. Jose Urquidez, M.d, M.D | Emergency Medical Services | Austin, TX | $207,952 | $0 |
| Eric Liu, M.d, M.D | Surgical Oncology | Denver, CO | $201,151 | $0 |
| Sarbajit Mukherjee | Medical Oncology | Miami, FL | $201,116 | $0 |
| Dr. Laxman Bahroo, D.o,, D.O, | Neurology | Washington, DC | $193,812 | $0 |
| Dr. Matthew Dugan, D.o, D.O | Hematology & Oncology | Westbrook, ME | $179,550 | $0 |
| Khashayar Dashtipour, M.d, M.D | Neurology | Loma Linda, CA | $174,174 | $0 |
| Atul Patel, M.d, M.D | Physical Medicine & Rehabilitation | Overland Park, KS | $172,063 | $0 |
| William Velasquez, M. D, M. D | Medical Oncology | Houston, TX | $163,212 | $0 |
| Dr. Nicholas Ketchum, M.d, M.D | Physical Medicine & Rehabilitation | Milwaukee, WI | $160,349 | $0 |
| Fadi Braiteh, M.d, M.D | Internal Medicine | Las Vegas, NV | $158,230 | $0 |
| Dr. Robert Ramirez, D.o, D.O | Internal Medicine | Nashville, TN | $143,508 | $0 |
| Mohammed Al Hallak, M.d, M.D | Hematology & Oncology | Detroit, MI | $137,423 | $0 |
| Aaron Ellenbogen, D.o, D.O | Neurology | Farmington Hills, MI | $133,555 | $0 |
| Sonal Kumar, Md, MD | Gastroenterology | New York, NY | $130,200 | $0 |
| Benjamin Musher, Md, MD | Hematology & Oncology | Houston, TX | $128,074 | $0 |
| Shivani Gupta, Do, DO | Pain Medicine | Oak Lawn, IL | $120,401 | $0 |
Ad
Top Products
- ONIVYDE $33.2M
- Onivyde $20.6M
Associated Products (8)
- ONIVYDE $46.2M
- Onivyde $24.3M
- SOMATULINE DEPOT $6.4M
- Somatuline Depot $4.1M
- Somatuline Depot 120mg-.5ml $1.5M
- IQIRVO $1.1M
- INCRELEX $895,740
- Sohonos $15,842
Payment Categories
- Food & Beverage $1.9M
- Consulting $2.5M
- Travel & Lodging $1.5M
- Research $68.1M
About Ipsen Biopharmaceuticals, Inc
Ipsen Biopharmaceuticals, Inc has made $86.1M in payments to 21,651 healthcare providers, recorded across 75,758 transactions in the CMS Open Payments database. In 2024, the company paid $16.7M. The top product by payment volume is ONIVYDE ($33.2M).
Payments were distributed across 216 medical specialties. The top specialty by payment amount is Hematology & Oncology ($2.9M to 2,745 doctors).
Payment categories include: Food & Beverage ($1.9M), Consulting ($2.5M), Research ($68.1M), Travel & Lodging ($1.5M).
Ipsen Biopharmaceuticals, Inc is associated with 8 products in the CMS Open Payments database, including ONIVYDE, Onivyde, and SOMATULINE DEPOT.